Battle against Covid-19 to Drive the Advanced Drug Delivery Systems market
As per Persistence Market Research, the global advanced drug delivery systems market will grow at a noteworthy CAGR going forward. Growing prevalence of the chronic diseases along with technological advancement are expected to drive the advanced drug delivery systems market. The current scenario is such that bioavailability of drugs is being focused on. Tremendous advancements are being witnessed with regards to biotechnology and nanotechnology, which is resulting in synthesis of chemoimmunoconjugates, peptide drugs, and biotechnology and nanotechnology-driven protein containing drugs. Apart from pharmacodynamics and molecular biology, pharmaceutical companies are looking out for the drug-eluting implants that serve the purpose with minimum dose. As of now, the potential phospholipid drug-conjugate, CLR 131 (by Cellectar Biosciences) is being examined as a drug delivery system for the cancer-affected patients. It has been rendered effective in treating B-cell malignancies (like multiple myeloma). This drug, once successful, could be looked upon even as an effective means for pain delivery. As such, pain drug delivery market is expected to reach higher strides between 2020 and 2030.